Press Releases
Page 2 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
BioMarin's PALYNZIQ Receives FDA Approval for Adolescent PKU Patients 12 and Older
BioMarin announces FDA approval of PALYNZIQ for adolescents 12+ with phenylketonuria (PKU), expanding treatment options for rare genetic disorder patients.
ROIS Expands to US Market as Global CDMO with FDA Approval for Injectable Drug Manufacturing
ROIS establishes US operations as global CDMO with FDA, EMA, and other major regulatory approvals for end-to-end injectable drug manufacturing services.
FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+
Travere Therapeutics receives FDA approval for FILSPARI to reduce proteinuria in FSGS patients aged 8 and older, expanding rare kidney disease treatment options.
UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases
UCB's $2.2B acquisition of Candid Therapeutics brings novel T-cell engager technology for autoimmune diseases, marking major expansion beyond oncology applications.
a2 Milk Company Recalls Three Batches of a2 Platinum Infant Formula Due to Health Risk Concerns
a2 Milk Company voluntarily recalls three batches of a2 Platinum Premium USA infant formula for 0-12 months due to potential health risks to babies.
Vector Science & Therapeutics Files Patent for Microneedle Catheter Platform for Cancer Drug Delivery
Vector Science & Therapeutics secures IP protection for novel microneedle catheter technology designed to deliver cancer drugs directly into tumors.
Apotex Receives First Canadian Health Canada Approval for Generic Ozempic (Semaglutide) Alternative
Apotex becomes first Canadian pharmaceutical company to receive Health Canada approval for Apo-Semaglutide Injection, a generic equivalent of Ozempic.
Keenova Therapeutics Presents New TERLIVAZ Clinical Data for Hepatorenal Syndrome at Digestive Disease Week 2026
Keenova Therapeutics shares new TERLIVAZ (terlipressin) clinical analysis for hepatorenal syndrome-acute kidney injury at DDW 2026, expanding treatment evidence.
Kodiak Sciences KSI-101 Clinical Data to Be Presented at Scientific Conferences for Macular Edema Treatment
Kodiak Sciences will present KSI-101 clinical data for macular edema secondary to inflammation, with Phase 3 results expected in Q4 2026.
NAMSA and Lexitas Form Strategic Partnership for Comprehensive Ophthalmic Medical Device Development Services
NAMSA partners with Lexitas Pharma Services to offer end-to-end ophthalmic medical device development, creating single-source solution for sponsors.
Verified Clinical Trials Partners with Chubb to Enhance Patient Safety and Data Quality in Clinical Research
Verified Clinical Trials and Chubb announce strategic alliance to improve clinical trial participant safety, data quality, and study integrity worldwide.
Huahui Health Partners with BeOne Medicines for HH160 Trispecific Antibody in Global Oncology Deal
Huahui Health grants BeOne Medicines exclusive worldwide rights to develop HH160, a novel trispecific antibody for cancer immunotherapy treatment.